Medical Cannabis for PTSD in Israel: Access, Funding and the 2026 Rules

Post-traumatic stress disorder is one of the largest — and by far the most contested — indications for medical cannabis in Israel. In a country with a large veteran population and, since October 2023, a sharp rise in trauma, demand has climbed even as the clinical evidence has come under harder scrutiny. In May 2026 a Health Ministry committee moved to narrow access for exactly this indication — and three days later the health minister froze the whole plan. This guide explains where things now stand.

This guide is informational and is not medical advice. PTSD is a serious condition; treatment decisions should be made with a qualified clinician.

A large and fast-growing indication

PTSD has been a recognised indication for medical cannabis in Israel since 2014. A comprehensive 2025 review counted 12,977 PTSD-licensed patients — about 8.2% of all medical cannabis users over the period studied, roughly 70% of them men (Journal of Cannabis Research, 2025). Its share of prescriptions has risen steeply, and by 2026 the Health Ministry put PTSD at about 17% of all cannabis patients in Israel (Times of Israel). It is the second-largest indication after chronic pain, and the fastest-growing.

That growth sits inside a much larger surge — and then a correction. National licence numbers climbed from roughly 33,000 in 2019, with the sharpest rise among men and people under 45 (Times of Israel), to a peak of 140,483 active licences in January 2024. The count then fell by about 7.5% to roughly 129,900 licences and prescriptions by March 2025 as the health funds tightened gatekeeping, before recovering to an all-time high of about 143,900 by May 2026 (Journal of Cannabis Research, 2025; Cannabis Magazine, 12 July 2026). The full arc behind those figures is traced in how many medical cannabis patients are in Israel. Regulators look at those curves and see a programme that started behaving like a consumer market. That perception is the backdrop to everything below.

Unlike most indications, which were devolved to the health funds, PTSD stayed under the direct authority of the Ministry of Health's Medical Cannabis Unit — a marker of how closely the state manages this category.

Reimbursement for combat-related cases

Because PTSD in Israel is heavily combat-related, a large share of patients are treated not through the ordinary health system but through the Ministry of Defense's Department of Rehabilitation, which provides full reimbursement of medical cannabis costs (Journal of Cannabis Research, 2025). For eligible disabled veterans, that removes the out-of-pocket burden other patients carry — see how much medical cannabis costs in Israel for what everyone else pays. War-related stress since late 2023 has further increased demand for cannabis as a trauma treatment (AJEM).

The efficacy debate — and why the ministry moved

The clinical picture is genuinely unsettled, and patients should understand that before they start.

A coalition of doctors treating PTSD published a report warning of potential harms in this indication, which prompted the Ministry of Health to convene a review committee headed by Dr. Gilad Bodenheimer, head of the ministry's mental health division (Jerusalem Post; The Media Line). The concern draws on wider evidence: a large review in The Lancet found cannabis does not effectively treat anxiety, depression or PTSD, and flagged risks including psychosis, dependence and the displacement of proven therapies. Against that, smaller studies of treatment-resistant combat PTSD have reported benefit in individual patients (Frontiers in Psychiatry, 2022).

The committee reported on 3 May 2026 and its conclusion was blunt: long-term harm from cannabis is proven, while the benefit for PTSD sufferers is not sufficiently borne out in the studies, and it worried specifically about patients' ability to return to normal functioning. Bodenheimer put the addiction risk at more than 20% — even among medical users — and warned that "there is a widespread belief among the public that cannabis is a magic cure, and this is not the case" (Times of Israel).

What the 2026 recommendations would change for PTSD patients

The committee did not recommend removing PTSD as an indication. It recommended making it much harder to qualify, and changing how it is treated (Times of Israel; Hemp Gazette; Jerusalem Post):

• Severe distress only. Cannabis would be approved for PTSD only in severe states — insomnia, significant agitation, flashbacks — rather than as a broad first option, aligning with the positions of the US FDA and Israel's National Council for Post-Trauma.
• Adjunct, not substitute. It would be prescribed alongside proven treatment such as psychotherapy, explicitly to stop cannabis displacing evidence-based care.
• Addiction screening. Physicians would assess addiction risk before starting treatment and sharpen the warning signs they monitor for, with treatment avoided where that risk is significant.
• A real renewal review. Continuing a prescription beyond six months would require an in-person meeting with the prescribing physician.
• No more smoking. Smokable cannabis would be phased out over three years in favour of oils, extracts and precision inhalers — a substantial change for a patient population that overwhelmingly smokes.
• Into the HMOs. Prescribing and dispensing would move into the health funds within about a year, ending the Medical Cannabis Unit's separate PTSD track.

Then the minister froze it

Every item above is a recommendation, not enacted law — and none of it is being implemented. On Wednesday 6 May 2026, three days after the committee published, Health Minister Haim Katz instructed the ministry's director-general to halt all work on implementing the recommendations, saying he "was not sufficiently convinced that there was justification for implementing the recommendations, given the potential harm to patients" (StratCann). Patient groups and clinicians who treat cannabis as a lifeline for veterans who failed other therapies had already begun pushing back before he did.

So nothing in the list above applies to a PTSD patient today. But a freeze is not a repeal: the recommendations came from the ministry's own professional committee, they have not been withdrawn, and a future minister can revive them. The full account is in is Israel banning smoked medical cannabis?.

What this means if you are considering it

PTSD remains an accessible, established indication in Israel, and combat-related cases may be fully funded through the Ministry of Defense. Because the 2026 package is frozen, none of it is a requirement today: there is no mandatory addiction screening, no six-month in-person renewal rule, and no phase-out of smokable products in force. What has shifted is the climate rather than the rules — the ministry's own professional committee has said the evidence does not support prescribing at current levels, and that argument has not gone away. Weigh it with a clinician who can set the possible benefit against the documented risks and the alternatives, particularly trauma-focused psychotherapy.

For how to apply, see how to get a medical cannabis licence in Israel; for the full list of recognised indications, see qualifying conditions for medical cannabis in Israel. The science behind the cannabinoid system is covered in the endocannabinoid system explained and our Research section; the broader access picture lives on the Patient Access hub.